Cohort Study of Chronic Heart Failure
1 other identifier
observational
20,000
0 countries
N/A
Brief Summary
The purpose is to understand the clinical characteristics of chronic heart failure as soon as possible, analyze the etiology, comorbidities, clinical characteristics, and treatment of heart failure patients, observe the gap between real-world clinical practice and guideline recommendations, and provide reference for the improvement of heart failure prevention and treatment in China.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2012
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 20, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
July 14, 2022
CompletedFirst Submitted
Initial submission to the registry
August 21, 2023
CompletedFirst Posted
Study publicly available on registry
October 23, 2023
CompletedOctober 23, 2023
October 1, 2023
8.6 years
August 21, 2023
October 19, 2023
Conditions
Outcome Measures
Primary Outcomes (3)
echocardiogram
ejection fraction,Consider heart failure when the ejection fraction is less than 50%
Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
cardiac marker
CK，CK-MB，cTnT，cTnI，Mb
Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
serum biochemical indicators
HDL-cholesterol, mg/dL，LDL-cholesterol, mg/dL，Total cholesterol, mg/dL，Triglycerides, mg/dL
Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
Secondary Outcomes (5)
Thyroid Function
Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
Coagulation function indicators
Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
Blood routine
Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
Blood routine
Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
Blood routine
Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
Study Arms (1)
No Intervention
No Intervention
Interventions
Eligibility Criteria
You may qualify if:
- Accompanied by difficulty breathing, fatigue, or decreased activity tolerance;
- Signs of fluid retention (pulmonary congestion and peripheral edema);
- Echocardiography shows abnormalities in cardiac structure and/or function;
- Elevated levels of natriuretic peptide: B-type natriuretic peptide (BNP)\>35 ng/L and/or N-terminal B-type proBNP (NT proBNP)\>125 ng/L.
You may not qualify if:
- Concomitant severe liver function, renal failure, or other severe system dysfunction
- Poor compliance, inability to obtain information, or voluntary refusal to participate in this study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Xiang Xielead
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- professor
Study Record Dates
First Submitted
August 21, 2023
First Posted
October 23, 2023
Study Start
November 20, 2012
Primary Completion
June 30, 2021
Study Completion
July 14, 2022
Last Updated
October 23, 2023
Record last verified: 2023-10